More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/DCC-2036 [1020172-07-9]

DCC-2036 [1020172-07-9]

Research Use Only
D0808
LKT Laboratories
Estimated Purity≥98%
Product group Chemicals
€ 192,00
5 mg
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    LKT Laboratories
  • Product Name
    DCC-2036 [1020172-07-9]
  • Delivery Days Customer
    7
  • Certification
    Research Use Only
  • Estimated Purity
    ≥98%
  • Format
    DMSO 111 mg/mL (200.5 mM); Ethanol 16 mg/mL (28.9 mM); Water Insoluble
  • Scientific Description
    Abl inhibitor.; DCC2036, Rebastinib
  • Storage Instruction
    -20°C
  • UNSPSC
    12352200

References

  • Shen Y, Shi X, Pan J. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRalfa. PLoS One. 2013 Aug 29;8(8):e73059. PMID: 24009732. Eide CA, Adrian LT, Tyner JW, et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011 May 1;71(9):3189-95. PMID: 21505103.